Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

ALUNBRIG improves progression-free survival in Phase 3
October 2018
SHARING OPTIONS:

CAMBRIDGE, Mass. & OSAKA, Japan—Takeda Pharmaceutical Company Ltd. announced earlier this year that its Phase 3 ALTA-1L trial had met its primary endpoint in the first pre-specified interim analysis. ALUNBRIG treatment led to a statistically significant improvement in progression-free survival compared to crizotinib in adults with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer who had not been previously treated with an ALK inhibitor. There were no new safety concerns associated with ALUNBRIG, as the drug candidate’s safety profile in the ALTA-1L trial proved generally consistent with established safety information.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.